HRP20211698T1 - Inhibitori za vezanje creb proteina (cbp) - Google Patents
Inhibitori za vezanje creb proteina (cbp) Download PDFInfo
- Publication number
- HRP20211698T1 HRP20211698T1 HRP20211698TT HRP20211698T HRP20211698T1 HR P20211698 T1 HRP20211698 T1 HR P20211698T1 HR P20211698T T HRP20211698T T HR P20211698TT HR P20211698 T HRP20211698 T HR P20211698T HR P20211698 T1 HRP20211698 T1 HR P20211698T1
- Authority
- HR
- Croatia
- Prior art keywords
- alkyl
- image
- compound according
- pharmaceutically acceptable
- cycloalkyl
- Prior art date
Links
- 108010040163 CREB-Binding Protein Proteins 0.000 title 1
- 102100021975 CREB-binding protein Human genes 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 21
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 13
- 150000003839 salts Chemical class 0.000 claims 11
- 125000000753 cycloalkyl group Chemical group 0.000 claims 8
- 125000000623 heterocyclic group Chemical group 0.000 claims 7
- 125000003118 aryl group Chemical group 0.000 claims 6
- 125000001072 heteroaryl group Chemical group 0.000 claims 6
- 125000004429 atom Chemical group 0.000 claims 4
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (15)
1. Spoj, naznačen time, da je predstavljen Formulom (I):
[image]
ili njegova farmaceutski prihvatljiva sol, enantiomer, hidrat, solvat, stereoizomer, ili njegov tautomer, pri čemu:
R1 je -OR5;
R5 je -C1-C6 alkil;
R6 je fenil koji je opcionalno supstituiran s jednim ili više R10;
svaki R10 je neovisno, kod svakog pojavljivanja, -C1-C6 alkil, -C2-C6 alkenil, -C2-C6 alkinil, -C3-C8 cikloalkil, -C4-C8 cikloalkenil, heterociklil, heteroaril, aril, -OH, halogen, -NO2, -CN, -NH2, -OC1-C6 alkil, -OC3-C6 cikloalkil, -Oaril, -Oheteroaril, NHC1-C6 alkil, N(C1-C6 alkil)2, -S(O)2NH(C1-C6 alkil), -S(O)2N(C1-C6 alkil)2, -S(O)2C1-C6 alkil, -C(O)C1-C6 alkil, -C(O)NH2, -C(O)NH(C1-C6 alkil), -C(O)N(C1-C6 alkil)2, -C(O)OC1-C6 alkil, -N(C1-C6 alkil)SO2C1-C6 alkil, -S(O)(C1-C6 alkil), -S(O)N(C1-C6 alkil)2, ili -N(C1-C6 alkil)S(O)(C1-C6 alkil), gdje je svaki alkil, alkenil, alkinil, cikloalkil, cikloalkenil, heterociklil, heteroaril ili aril opcionalno supstituiran s jednim ili više -R12;
pri čemu se bilo koja dva R10 kada su na nesusjednim atomima, mogu kombinirati kako bi tvorili premoštavajući cikloalkil ili heterociklil;
pri čemu se bilo koja dva R10 kada su na susjednim atomima, mogu kombinirati kako bi tvorili cikloalkil, heterociklil, aril ili heteroaril;
R12 je neovisno, kod svakog pojavljivanja, -C1-C6 alkil, -C2-C6 alkenil, -C2-C6 alkinil, -C3-C8 cikloalkil, -C4-C8 cikloalkenil, heterociklil, heteroaril, aril, -OH, halogen, okso, -NO2, -CN, -NH2, -OC1-C6 alkil, NHC1-C6 alkil, N(C1-C6 alkil)2, -S(O)2NH(C1-C6 alkil), -S(O)2N(C1-C6 alkil)2, -S(O)2C1-C6 alkil, -C(O)C1-C6 alkil, -C(O)NH2, -C(O)NH(C1-C6 alkil), -C(O)N(C1-C6 alkil)2, -C(O)OC1-C6 alkil, -N(C1-C6 alkil)SO2C1-C6 alkil, -S(O)(C1-C6 alkil), -S(O)N(C1-C6 alkil)2, ili -N(C1-C6 alkil)S(O)(C1-C6 alkil).
2. Spoj prema patentnom zahtjevu 1, ili njegova farmaceutski prihvatljiva sol, enantiomer, hidrat, solvat, stereoizomer, ili njegov tautomer, naznačen time, da
R5 je -C1-C3 alkil;
svaki R10 je neovisno, kod svakog pojavljivanja, -OC1-C6 alkil, -OC3-C6 cikloalkil, -Oaril, ili -Oheteroaril, pri čemu je svaki alkil, cikloalkil, aril ili heteroaril opcionalno supstituiran s jednim ili više -R12;
R12 je halogen.
3. Spoj prema patentnom zahtjevu 1, ili njegova farmaceutski prihvatljiva sol, naznačeni time, da se bilo koja dva R10 kada su na nesusjednim atomima, mogu kombinirati kako bi tvorili premoštavajući cikloalkil ili heterociklil.
4. Spoj prema patentnom zahtjevu 1, ili njegova farmaceutski prihvatljiva sol, naznačeni time, da se bilo koja dva R10 kada su na susjednim atomima, mogu kombinirati kako bi tvorili cikloalkil, heterociklil, aril ili heteroaril.
5. Spoj prema patentnom zahtjevu 1, naznačen time, da R5 jest metil.
6. Spoj prema patentnom zahtjevu 5, naznačen time, da najmanje jedan R10 je -OC1-C6 alkil.
7. Spoj prema patentnom zahtjevu 5, naznačen time, da najmanje jedan R10 je -C1-C6 alkil.
8. Spoj prema patentnom zahtjevu 5, naznačen time, da najmanje jedan R10 je -OC3-C6 cikloalkil.
9. Spoj prema patentnom zahtjevu 1, ili njegova farmaceutski prihvatljiva sol, naznačeni time, da se spoj bira od:
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
10. Spoj prema patentnom zahtjevu 1, ili njegova farmaceutski prihvatljiva sol, naznačen time, da spoj ima strukturu
[image]
11. Spoj prema patentnom zahtjevu 1, ili njegova farmaceutski prihvatljiva sol, naznačen time, da spoj ima strukturu
[image]
12. Spoj prema patentnom zahtjevu 1, ili njegova farmaceutski prihvatljiva sol, naznačen time, da spoj ima strukturu
[image]
13. Spoj prema patentnom zahtjevu 1, ili njegova farmaceutski prihvatljiva sol, naznačen time, da spoj ima strukturu
[image]
14. Spoj prema patentnom zahtjevu 1, ili njegova farmaceutski prihvatljiva sol, naznačen time, da spoj ima strukturu
[image]
15. Farmaceutski pripravak, naznačen time, da sadrži spoj prema bilo kojem od patentnih zahtjeva 1 do 14, ili njegovu farmaceutski prihvatljivu sol, i farmaceutski prihvatljiv nosač.
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862692593P | 2018-06-29 | 2018-06-29 | |
| PCT/US2018/051214 WO2019055869A1 (en) | 2017-09-15 | 2018-09-14 | TETRAHYDROIMIDAZO QUINOLINE COMPOSITIONS AS INHIBITORS OF CBP / P300 |
| PCT/US2018/051235 WO2019055877A1 (en) | 2017-09-15 | 2018-09-14 | TETRAHYDROIMIDAZO QUINOLINE COMPOSITIONS AS INHIBITORS OF CBP / P300 |
| US201962819490P | 2019-03-15 | 2019-03-15 | |
| PCT/US2019/039936 WO2020006483A1 (en) | 2018-06-29 | 2019-06-28 | Inhibiting creb binding protein (cbp) |
| US16/457,596 US10870648B2 (en) | 2018-06-29 | 2019-06-28 | Inhibiting CREB binding protein (CBP) |
| EP19183741.8A EP3587418B1 (en) | 2018-06-29 | 2019-07-01 | Inhibitors of creb binding protein (cbp) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20211698T1 true HRP20211698T1 (hr) | 2022-02-18 |
Family
ID=68987627
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20211698TT HRP20211698T1 (hr) | 2018-06-29 | 2019-07-01 | Inhibitori za vezanje creb proteina (cbp) |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US10870648B2 (hr) |
| EP (1) | EP3998266A1 (hr) |
| JP (3) | JP6781806B2 (hr) |
| KR (1) | KR20210025631A (hr) |
| CN (2) | CN116178369A (hr) |
| AU (2) | AU2019295790B2 (hr) |
| BR (1) | BR112020026783A2 (hr) |
| CA (1) | CA3105099A1 (hr) |
| CY (1) | CY1124762T1 (hr) |
| DK (1) | DK3587418T3 (hr) |
| ES (1) | ES2900105T3 (hr) |
| HR (1) | HRP20211698T1 (hr) |
| HU (1) | HUE056885T2 (hr) |
| IL (1) | IL279734A (hr) |
| LT (1) | LT3587418T (hr) |
| MA (1) | MA50675B1 (hr) |
| MX (2) | MX2020014303A (hr) |
| PL (1) | PL3587418T3 (hr) |
| PT (1) | PT3587418T (hr) |
| RS (1) | RS62732B1 (hr) |
| SG (1) | SG11202012767UA (hr) |
| SI (1) | SI3587418T1 (hr) |
| WO (1) | WO2020006483A1 (hr) |
| ZA (1) | ZA202100509B (hr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2020014303A (es) * | 2018-06-29 | 2021-03-25 | Forma Therapeutics Inc | Inhibición de la proteína de union a creb (cbp). |
| BR112021018266A2 (pt) * | 2019-03-15 | 2022-02-01 | Forma Therapeutics Inc | Composições e métodos para tratar formas positivas de receptor andrógeno de câncer |
| US20230233558A1 (en) | 2020-06-25 | 2023-07-27 | Tolremo Therapeutics Ag | Combination of a cbp/p300 bromodomain inhibitor and a kras inhibitor for the treatment of cancer |
| EP4171556A1 (en) | 2020-06-25 | 2023-05-03 | Tolremo Therapeutics AG | A combination of a cbp/p300 bromodomain inhibitor and an egfr inhibitor for use in treating egfr-mutant nsclc |
| US11801243B2 (en) | 2020-09-23 | 2023-10-31 | Forma Therapeutics, Inc. | Bromodomain inhibitors for androgen receptor-driven cancers |
| US11795168B2 (en) * | 2020-09-23 | 2023-10-24 | Forma Therapeutics, Inc. | Inhibiting cyclic amp-responsive element-binding protein (CREB) binding protein (CBP) |
Family Cites Families (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4404207A (en) | 1981-11-06 | 1983-09-13 | Riker Laboratories, Inc. | Antimicrobial 8-substituted benzo [IJ]quinolizines |
| AU1868195A (en) | 1994-01-28 | 1995-08-15 | Cell Therapeutics, Inc. | Cell signaling inhibitors |
| US6011029A (en) | 1996-02-26 | 2000-01-04 | Bristol-Myers Squibb Company | Inhibitors of farnesyl protein transferase |
| US6455564B1 (en) | 1999-01-06 | 2002-09-24 | Pharmacia & Upjohn Company | Method of treating sexual disturbances |
| US7101869B2 (en) | 1999-11-30 | 2006-09-05 | Pfizer Inc. | 2,4-diaminopyrimidine compounds useful as immunosuppressants |
| US7345051B2 (en) | 2000-01-31 | 2008-03-18 | Genaera Corporation | Mucin synthesis inhibitors |
| JP5355838B2 (ja) | 2000-11-20 | 2013-11-27 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | キラルな光異性化可能な化合物 |
| WO2003033517A1 (en) | 2001-10-17 | 2003-04-24 | The University Of British Columbia | Ship 1 modulators |
| WO2003045929A1 (fr) | 2001-11-26 | 2003-06-05 | Takeda Chemical Industries, Ltd. | Derive bicyclique, procede de production de ce derive et utilisation correspondante |
| HUP0203976A3 (en) | 2002-11-15 | 2004-08-30 | Sanofi Aventis | Adenozine a3 receptors, process for their preparation and pharmaceutical compositions containing them |
| TWI322012B (en) | 2002-12-20 | 2010-03-21 | Organon Nv | Tetrahydroquinoline derivatives |
| IN2003CH00929A (hr) | 2003-11-13 | 2008-10-06 | ||
| US20080188527A1 (en) | 2003-12-23 | 2008-08-07 | Cashman John R | Synthetic Compounds and Derivatives as Modulators of Smoking or Nicotine Ingestion and Lung Cancer |
| CA2562244A1 (en) | 2004-04-07 | 2005-10-27 | Takeda Pharmaceutical Company Limited | Cyclic compounds |
| US20060106020A1 (en) | 2004-04-28 | 2006-05-18 | Rodgers James D | Tetracyclic inhibitors of Janus kinases |
| WO2007120339A1 (en) | 2005-12-19 | 2007-10-25 | Genentech, Inc. | Pyrimidine kinase inhibitors |
| US20070203236A1 (en) | 2006-01-11 | 2007-08-30 | Smith Jeffrey W | Novel antagonists of the human fatty acid synthase thioesterase |
| EA200802213A1 (ru) | 2006-05-09 | 2009-10-30 | Химекуэст Фармасьютикалз, Инк. | Способы лечения заболеваний крови |
| EP1878724A1 (en) | 2006-07-15 | 2008-01-16 | sanofi-aventis | A regioselective palladium catalyzed synthesis of benzimidazoles and azabenzimidazoles |
| CA2574531C (en) | 2007-01-19 | 2016-10-25 | The University Of British Columbia | Hat acetylation promoters and uses of compositions thereof in promoting immunogenicity |
| US8476458B2 (en) | 2007-06-21 | 2013-07-02 | The Wistar Institute | Methods and compositions for modulating P300/CBP activity |
| KR20100023907A (ko) | 2007-06-26 | 2010-03-04 | 사노피-아벤티스 | 벤즈이미다졸 및 아자벤즈이미다졸의 위치선택적 구리 촉매화 합성 |
| WO2009001817A1 (ja) | 2007-06-27 | 2008-12-31 | Taisho Pharmaceutical Co., Ltd. | １１β－ＨＳＤ１阻害活性を有する化合物 |
| TW200930369A (en) | 2007-11-15 | 2009-07-16 | Astrazeneca Ab | Bis-(sulfonylamino) derivatives in therapy |
| AR072008A1 (es) | 2008-06-13 | 2010-07-28 | Merck & Co Inc | Compuestos heterobiciclicos como agentes de inhibicion de quinasa p38 |
| PT3289876T (pt) | 2008-06-16 | 2022-10-28 | Univ Tennessee Res Found | Compostos para o tratamento do câncer |
| EP2412710A4 (en) * | 2009-03-27 | 2012-08-08 | Kowa Co | CONDENSED PIPERIDINE COMPOUND AND PHARMACEUTICAL AGENT CONTAINING THE SAME |
| US20100305093A1 (en) | 2009-04-09 | 2010-12-02 | Exelixis, Inc. | Inhibitors of mTOR and Methods of Making and Using |
| CA2758904C (en) | 2009-04-15 | 2017-04-04 | Jw Pharmaceutical Corporation | Novel compounds of reverse-turn mimetics, method for manufacturing the same and use thereof |
| MX2011012584A (es) | 2009-05-26 | 2012-02-21 | Exelixis Inc | Benzoxazepinas como inhibidores de pi3k/m tor, metodos para su uso y fabricación. |
| WO2010138490A1 (en) | 2009-05-26 | 2010-12-02 | Exelixis, Inc. | Benzoxazepines as inhibitors of mtor and methods of their use and manufacture |
| WO2011085039A2 (en) | 2010-01-05 | 2011-07-14 | The Johns Hopkins University | Use of histone acetyltransferase inhibitors as novel anti-cancer therapies |
| RU2581367C2 (ru) | 2010-03-01 | 2016-04-20 | Джи Ти Икс, ИНК. | Соединения для лечения рака |
| NZ705135A (en) * | 2010-05-26 | 2017-10-27 | Sunovion Pharmaceuticals Inc | Heteroaryl compounds and methods of use thereof |
| WO2012019093A1 (en) | 2010-08-05 | 2012-02-09 | Human Biomolecular Research Institute | Synthetic compounds and methods to decrease nicotine self-administration |
| ES2553610T3 (es) | 2010-12-14 | 2015-12-10 | Electrophoretics Limited | Inhibidores de la caseína cinasa 1 delta (CK1delta) |
| US8765978B2 (en) | 2010-12-16 | 2014-07-01 | Transitions Optical, Inc. | Method of making indeno-fused naphthol materials |
| WO2012116135A2 (en) | 2011-02-24 | 2012-08-30 | Emory University | Noggin blocking compositions for ossification and methods related thereto |
| UY34171A (es) | 2011-07-01 | 2013-01-31 | Gilead Sciences Inc | Compuestos heterocíclicos fusionados como moduladores del canal iónico |
| GB201111705D0 (en) | 2011-07-07 | 2011-08-24 | Takeda Pharmaceutical | Compounds and their use |
| WO2013148114A1 (en) | 2012-03-30 | 2013-10-03 | University Of Florida Research Foundation, Inc. | P300/cbp inhibitors and methods of use |
| US9211333B2 (en) | 2012-06-05 | 2015-12-15 | Hong Kong Baptist University | Anti-cancer agents synthesized based on miliusane compounds |
| EP2897962A1 (en) | 2012-09-21 | 2015-07-29 | Advinus Therapeutics Limited | Substituted fused tricyclic compounds, compositions and medicinal applications thereof |
| RU2543485C2 (ru) | 2013-02-26 | 2015-03-10 | Андрей Александрович Иващенко | Гетероциклические агонисты рецепторов желчных кислот tgr5, фармацевтическая композиция, способы их получения и применения |
| TWI527811B (zh) | 2013-05-09 | 2016-04-01 | 吉李德科學股份有限公司 | 作爲溴結構域抑制劑的苯並咪唑衍生物 |
| EA035601B1 (ru) | 2013-06-21 | 2020-07-14 | Зенит Эпидженетикс Лтд. | Бициклические ингибиторы бромодомена |
| CA2915561C (en) | 2013-06-21 | 2020-09-22 | Zenith Epigenetics Corp. | Novel substituted bicyclic compounds as bromodomain inhibitors |
| US9975896B2 (en) | 2013-07-25 | 2018-05-22 | Dana-Farber Cancer Institute, Inc. | Inhibitors of transcription factors and uses thereof |
| DE102013215912B3 (de) | 2013-08-12 | 2015-02-26 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Farbneutral beschichteter kupferhaltiger Gegenstand, Verfahren zu dessen Herstellung sowie Verwendung einer entsprechenden farbneutralen Beschichtung |
| UY35834A (es) | 2013-11-14 | 2015-05-29 | Bristol Myers Squibb Company Una Corporación Del Estado De Delaware | Piperazinas de pirazolo sustituido como inhibidores de caseína quinasa 1 delta y epsilon |
| US9422281B2 (en) | 2013-11-18 | 2016-08-23 | Forma Therapeutics, Inc. | Benzopiperazine compositions as BET bromodomain inhibitors |
| AU2014348191B2 (en) | 2013-11-18 | 2019-03-28 | Forma Therapeutics Inc. | Tetrahydroquinoline compositions as BET bromodomain inhibitors |
| WO2016044694A1 (en) | 2014-09-19 | 2016-03-24 | Genentech, Inc. | Use of cbp/ep300 and bet inhibitors for treatment of cancer |
| JP6771464B2 (ja) * | 2014-11-27 | 2020-10-21 | ジェネンテック， インコーポレイテッド | Ｃｂｐおよび／またはｅｐ３００インヒビターとしての、４，５，６，７−テトラヒドロ−１ｈ−ピラゾロ［４，３−ｃ］ピリジン−３−アミン化合物 |
| BR112017014770A2 (pt) | 2015-01-08 | 2018-01-16 | Advinus Therapeutics Ltd | compostos bicíclicos, composições e aplicações médicas dos mesmos |
| WO2016128908A1 (en) | 2015-02-12 | 2016-08-18 | Advinus Therapeutics Limited | Bicyclic compounds, compositions and medicinal applications thereof |
| GB201506658D0 (en) | 2015-04-20 | 2015-06-03 | Cellcentric Ltd | Pharmaceutical compounds |
| GB201506660D0 (en) | 2015-04-20 | 2015-06-03 | Cellcentric Ltd | Pharmaceutical compounds |
| WO2017197056A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Bromodomain targeting degronimers for target protein degradation |
| CA3024556A1 (en) | 2016-05-12 | 2017-11-16 | The Regents Of The University Of Michigan | Ash1l inhibitors and methods of treatment therewith |
| WO2017205536A2 (en) | 2016-05-24 | 2017-11-30 | Genentech, Inc. | Therapeutic compounds and uses thereof |
| GB201617630D0 (en) | 2016-10-18 | 2016-11-30 | Cellcentric Ltd | Pharmaceutical compounds |
| GB201617627D0 (en) | 2016-10-18 | 2016-11-30 | Cellcentric Ltd | Pharmaceutical compounds |
| EP3612522A4 (en) * | 2017-04-18 | 2021-07-07 | Celgene Quanticel Research, Inc. | THERAPEUTIC COMPOUNDS |
| WO2019055877A1 (en) * | 2017-09-15 | 2019-03-21 | Forma Therapeutics, Inc. | TETRAHYDROIMIDAZO QUINOLINE COMPOSITIONS AS INHIBITORS OF CBP / P300 |
| MX2020014303A (es) * | 2018-06-29 | 2021-03-25 | Forma Therapeutics Inc | Inhibición de la proteína de union a creb (cbp). |
-
2019
- 2019-06-28 MX MX2020014303A patent/MX2020014303A/es unknown
- 2019-06-28 KR KR1020217002866A patent/KR20210025631A/ko active Search and Examination
- 2019-06-28 SG SG11202012767UA patent/SG11202012767UA/en unknown
- 2019-06-28 WO PCT/US2019/039936 patent/WO2020006483A1/en active Application Filing
- 2019-06-28 BR BR112020026783-0A patent/BR112020026783A2/pt unknown
- 2019-06-28 US US16/457,596 patent/US10870648B2/en active Active
- 2019-06-28 CA CA3105099A patent/CA3105099A1/en active Pending
- 2019-06-28 AU AU2019295790A patent/AU2019295790B2/en active Active
- 2019-06-28 CN CN202211658329.8A patent/CN116178369A/zh active Pending
- 2019-06-28 CN CN201980050022.XA patent/CN112513038B/zh active Active
- 2019-07-01 ES ES19183741T patent/ES2900105T3/es active Active
- 2019-07-01 HU HUE19183741A patent/HUE056885T2/hu unknown
- 2019-07-01 JP JP2019123100A patent/JP6781806B2/ja active Active
- 2019-07-01 DK DK19183741.8T patent/DK3587418T3/da active
- 2019-07-01 EP EP21193994.7A patent/EP3998266A1/en active Pending
- 2019-07-01 LT LTEP19183741.8T patent/LT3587418T/lt unknown
- 2019-07-01 PT PT191837418T patent/PT3587418T/pt unknown
- 2019-07-01 HR HRP20211698TT patent/HRP20211698T1/hr unknown
- 2019-07-01 MA MA50675A patent/MA50675B1/fr unknown
- 2019-07-01 RS RS20211321A patent/RS62732B1/sr unknown
- 2019-07-01 PL PL19183741T patent/PL3587418T3/pl unknown
- 2019-07-01 SI SI201930136T patent/SI3587418T1/sl unknown
-
2020
- 2020-05-28 JP JP2020093126A patent/JP7017801B2/ja active Active
- 2020-06-08 US US16/946,159 patent/US11254674B2/en active Active
- 2020-12-17 JP JP2020209005A patent/JP2021042255A/ja active Pending
- 2020-12-18 MX MX2023013508A patent/MX2023013508A/es unknown
- 2020-12-23 IL IL279734A patent/IL279734A/en unknown
-
2021
- 2021-01-25 ZA ZA2021/00509A patent/ZA202100509B/en unknown
- 2021-11-22 CY CY20211101010T patent/CY1124762T1/el unknown
-
2022
- 2022-02-10 US US17/669,112 patent/US20220162207A1/en active Pending
-
2023
- 2023-09-05 AU AU2023226653A patent/AU2023226653A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20211698T1 (hr) | Inhibitori za vezanje creb proteina (cbp) | |
| HRP20211041T1 (hr) | Anthelmintski depsipeptidni spojevi | |
| HRP20191932T1 (hr) | Sinteza boronatnih soli i njihove uporabe | |
| HRP20221112T1 (hr) | Derivati benzodiazepina kao inhibitori rsv | |
| HRP20211218T1 (hr) | Inhibitori receptora fibroblastnog faktora rasta | |
| HRP20160350T1 (hr) | Heterociklički spojevi i njihove uporabe | |
| HRP20200538T1 (hr) | Derivati pirimidina za liječenje virusnih infekcija | |
| HRP20230342T1 (hr) | Kationski lipid koji se može ionizirati za isporuku rna | |
| HRP20200179T1 (hr) | Spojevi heteroarila kao inhibitori irak i njihova uporaba | |
| HRP20200648T1 (hr) | Derivati sulfamoilpirolamida i njihova uporaba kao lijekova za liječenje hepatitisa b | |
| HRP20211949T1 (hr) | Derivat pirazol primidina i njegove uporabe | |
| DK3606909T3 (da) | Natriumsalt af n-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1-isopropyl-1h-pyrazol-3-sulfonamid | |
| HRP20221018T1 (hr) | Liječenje katapleksije | |
| BR112018007527A2 (pt) | compostos de pirazolona ou sais dos mesmos, método de preparação dos mesmos, composição herbicida e uso dos mesmos | |
| HRP20231742T1 (hr) | Kationski lipid koji se može ionizirati za isporuku rna | |
| RS54264B1 (en) | 4-ARYL-N-PHENYL-1,3,5-TRIAZINE-2-AMINES CONTAINING SULPHOXIMINE GROUP | |
| HRP20211923T1 (hr) | Pirimidin-2-ilamino-1h-pirazoli kao inhibitori lrrk2 za uporabu u liječenju neurodegenerativnih poremećaja | |
| RS51097B (sr) | Glukokortikoidni mimetici,postupci za njihovo dobijanje, farmaceutski preparati i njihova primena | |
| HRP20120735T1 (hr) | Derivati fosfonske kiseline i njihova uporaba kao antagonista p2y12 receptora | |
| HRP20220840T1 (hr) | Inhibitori receptora faktora rasta fibroblasta | |
| RS54355B1 (en) | Isoxazole-pyridine derivatives | |
| HRP20140011T1 (hr) | Derivati oksazina i njihova uporaba u lijeäśenju neuroloških poremeä†aja | |
| RS53717B1 (en) | 1-aryl-3-aminoalkoxy pyrazoles as SIGMA ligands that increase the analgesic effect of opioids and reduce their dependence on them | |
| HRP20230261T1 (hr) | Peptidi za ciljanje mitohondrija | |
| RU2019107162A (ru) | Конденсированные бициклические гетероциклические производные в качестве средств для борьбы с вредителями |